Next Article in Journal
Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants
Next Article in Special Issue
Mutual Balance between Vasohibin-1 and Soluble VEGFR-1 in Endothelial Cells
Previous Article in Journal
Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of ActionOral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action
Previous Article in Special Issue
Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action
Article Menu

Export Article

Open AccessReview
Pharmaceuticals 2010, 3(10), 3021-3039; doi:10.3390/ph3103021

Endogenous Matrix-Derived Inhibitors of Angiogenesis

1
Department of Surgery, Umea University Hospital, Umea University, SE-90185 Umea, Sweden
2
Department of Diagnostics and Oral Medicine, Institute of Dentistry, University of Oulu, Oulu, Finland
3
Department of Oncology, Institute of Medicine, Haukeland University Hospital, University of Bergen, Bergen, Norway
*
Author to whom correspondence should be addressed.
Received: 10 August 2010 / Revised: 19 September 2010 / Accepted: 25 September 2010 / Published: 28 September 2010
(This article belongs to the Special Issue Angiogenesis Inhibitors)
View Full-Text   |   Download PDF [404 KB, uploaded 28 September 2010]   |  

Abstract

Endogenous inhibitors of angiogenesis are proteins or fragments of proteins that are formed in the body, which can inhibit the angiogenic process. These molecules can be found both in the circulation and sequestered in the extracellular matrix (ECM) surrounding cells. Many matrix-derived inhibitors of angiogenesis, such as endostatin, tumstatin, canstatin and arresten, are bioactive fragments of larger ECM molecules. These substances become released upon proteolysis of the ECM and the vascular basement membrane (VBM) by enzymes of the tumor microenvironment. Although the role of matrix-derived angiogenesis inhibitors is well studied in animal models of cancer, their role in human cancers is less established. In this review we discuss the current knowledge about these molecules and their potential use as cancer therapeutics and biomarkers. View Full-Text
Keywords: angiogenesis; extracellular matrix; collagen; cancer; therapy; biomarker angiogenesis; extracellular matrix; collagen; cancer; therapy; biomarker
Figures

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Sund, M.; Nyberg, P.; Eikesdal, H.P. Endogenous Matrix-Derived Inhibitors of Angiogenesis. Pharmaceuticals 2010, 3, 3021-3039.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top